A Massachusetts-based biotech company is stealing the mid-week spotlight so far during Wednesday’s session after the company announced Q3 2024 GAAP EPS of $(0.09), which...

To read the full story on AllPennyStocks.com, click here.

Mersana Therapeutics (NASDAQ:MRSN)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025 Plus de graphiques de la Bourse Mersana Therapeutics
Mersana Therapeutics (NASDAQ:MRSN)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025 Plus de graphiques de la Bourse Mersana Therapeutics